PBRM1-BD2-IN-5

Research use only, not for human use.

PBRM1-BD2-IN-5 is a potent inhibitor of the PBRM1 Bromodomain, with dissociation constant (Kd) values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5 respectively, and an inhibitory concentration 50 (IC50) value of 0.26 μM for PBRM1-BD2.

PBRM1-BD2-IN-5 is a potent PBRM1 Bromodomain inhibitor with Kd values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5, respectively, and an IC50 value of 0.26 μM for PBRM1-BD2. PBRM1-BD2-IN-5 reduces the binding of full-length PBRM1 within the PBAF complex in cell lysates to acetylated histone peptide. PBRM1-BD2-IN-5 can be used to research anticancer.

PBRM1-BD2-IN-5 (compound 16) (0-10 μM; 5 days) inhibits PBRM1-expressed LNCaP cells, and reduces the binding of full-length PBRM1 within the PBAF complex in cell lysates to acetylated histone peptides.Cell Viability Assay Cell Line:LNCaP cells expressing lentiviral shPBRM1 Concentration:0, 0.1, 1 and 10 μM Incubation Time:5 days Result:Exhibited a more significant effect on LNCaP viability in cells with native PBRM1 levels than in cells with PBRM1 knockdown.Reduced the binding of full-length PBRM1 within the PBAF complex in cell lysates to acetylated histone peptides.

——

——

Chromatin/Epigenetic

Epigenetic Reader Domain

Epigenetic Reader Domain

——

——

2819989-61-0

272.73

C15H13ClN2O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (366.66 mM; Ultrasonic )

O=C1C=2C(NC(N1)C3=CC(C)=CC=C3)=CC=CC2Cl

——

(-20℃)

With Ice Pack

≥ 2 years